市场调查报告书
商品编码
1215393
全球潜伏性结核传染病 (LTBI) 检测市场规模调查和预测:按测试类型、最终用户和地区分析,2022-2029 年Global Latent Tuberculosis Infection Detection Market Size study & Forecast, by Test Type, by End-User and Regional Analysis, 2022-2029 |
潜伏性结核感染是一种细菌在体内休眠而不活跃的结核感染。
通过结核菌素皮肤试验 (TST) 检测。 其他疾病会增加风险,例如药物滥用、艾滋病毒和削弱免疫系统的药物。 结核病检测需求激增、管理疾病治疗的资金增加以及老年人口增加等因素正在推动全球市场增长。
由潜伏性结核感染 (LTBI) 发展为活动性结核病的风险不断上升正在推动全球市场需求。 据 TBFacts.org 称,到 2021 年,估计约有 40% 的印度人会感染结核桿菌,其中大多数患有潜伏性结核病,而不是活动性结核病。 同样,美国疾病控制与预防中心 2021 年的一份报告估计,美国有多达 1300 万人患有潜伏性结核病感染。 因此,人群中潜伏性结核感染的高患病率正在促进市场增长。 此外,非政府组织和市场参与者开展的提高认识运动,以及政府加大治疗潜伏性结核病的力度,在未来几年创造了多种机会。 然而,缺乏系统的结核病筛查方法、缺乏适当的建议和报销政策阻碍了整个 2022-2029 年预测期内的市场增长。
全球潜伏性结核感染检测市场研究中考虑的主要区域是亚太地区、北美、欧洲、拉丁美洲和世界其他地区。 由于对感染早期诊断意识的提高、结核病控制的高额资金以及医疗保健设施的改善,北美在收入方面占据了市场主导地位。 另一方面,预计亚太地区在预测期内将以最高复合年增长率增长。 新兴国家的高感染率、人口增长和有利的政府举措等因素在预测期内推动了市场增长。
这项研究的目的是揭示近年来各个细分市场和国家/地区的市场规模,并预测未来几年的市场规模。 本报告旨在捕捉被调查国家行业的定性和定量方面的情况。
它还提供了关键方面的详细信息,例如决定市场未来增长的驱动因素和挑战。 此外,它还包含供利益相关者投资的微观市场潜在机会,以及对主要参与者的竞争格局和产品供应的深入分析。
Global Latent Tuberculosis Infection Detection Market is valued at approximately USD XX billion in 2021 and is anticipated to grow with a healthy growth rate of more than XX% over the forecast period 2022-2029. Latent Tuberculosis Infection (LTBI) is a variety of TB infection in which bacteria remains inactive specifically bacteria that exists in the sleeping state inside the individual's body. The detection of this infection is identified by the tuberculin skin test (TST). The risk is increased by other diseases including drug abuse, HIV, or medications that weakens the immune system. Factors such as surging demand for tuberculosis testing, growing funding to manage disease treatment, and increasing geriatric population are driving the market growth globally.
The rising risk of developing active TB from latent tuberculosis infection (LTBI) is propelling the demand for market across the globe. According to TBFacts.org, in 2021, about 40% of Indians are estimated to be infected with the TB bacteria, with the great majority having latent TB instead of active TB disease. Likewise, according to the Centers for Disease Control and Prevention report 2021, it was estimated that up to 13 million people in the United States suffered from latent TB infection. Therefore, the high prevalence rate of latent tuberculosis infection among the population is augmenting the market growth. Furthermore, growing awareness campaigns conducted by non-government bodies and market players, as well as a rising number of government initiatives to treat LTBI are leveraging multiple opportunities in the foreseen years. However, the lack of a systematic approach to screening tuberculosis and the unavailability of proper recommendations and reimbursement policies are hindering market growth throughout the forecast period of 2022-2029.
The key regions considered for the Global Latent Tuberculosis Infection Detection Market study include Asia Pacific, North America, Europe, Latin America, and the Rest of the World. North America dominated the market in terms of revenue, owing to the growing awareness about early diagnosis of infection, high funding for tuberculosis management, and improvement of healthcare facilities. Whereas, Asia Pacific is expected to grow at the highest CAGR during the forecast period. Factors such as high infection rates in developing countries, increasing population, as well as government favorable initiatives are burgeoning the market growth in the forecasting years.
Major market players included in this report are:
QIAGEN N.V.
Oxford Immunotec Inc.
F. Hoffmann-La Roche Ltd.
Sanofi S.A.
Abbott Laboratories
bioMerieux SA
Becton, Dickinson, and Company
Endo International plc
PerkinElmer, Inc.
Bruker Corporation
Recent Developments in the Market:
Global Latent Tuberculosis Infection Detection Market Report Scope:
Historical Data: 2019-2020-2021
Base Year for Estimation: 2021
Forecast period: 2022-2029
Report Coverage: Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Segments Covered: Test Type, End-User, Region
Regional Scope: North America; Europe; Asia Pacific; Latin America; Rest of the World
Customization Scope: Free report customization (equivalent up to 8 analyst's working hours) with purchase. Addition or alteration to country, regional & segment scope*
The objective of the study is to define the market sizes of different segments & countries in recent years and to forecast the values for the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within the countries involved in the study.
The report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with a detailed analysis of the competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:
By Test Type:
Tuberculin Skin Test
Interferon Gamma Release Assays
By End User:
Diagnostic Laboratories
Hospitals/Clinics
Academic & Research Institutions
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
ROLA
Rest of the World
List of tables and figures and dummy in nature, final lists may vary in the final deliverable
List of figures
List of tables and figures and dummy in nature, final lists may vary in the final deliverable